Mithra Pharmaceuticals SA (OTCMKTS:MITPF) Sees Large Drop in Short Interest

Mithra Pharmaceuticals SA (OTCMKTS:MITPFGet Rating) was the target of a large decrease in short interest in August. As of August 31st, there was short interest totalling 171,200 shares, a decrease of 10.5% from the August 15th total of 191,200 shares. Based on an average trading volume of 300 shares, the short-interest ratio is currently 570.7 days.

Mithra Pharmaceuticals Stock Down 12.9 %

Shares of MITPF opened at $6.75 on Monday. Mithra Pharmaceuticals has a 1 year low of $6.75 and a 1 year high of $7.75. The business’s 50 day simple moving average is $12.10 and its 200-day simple moving average is $18.97.

Analyst Ratings Changes

Separately, Berenberg Bank decreased their price objective on Mithra Pharmaceuticals from €41.00 ($41.84) to €31.00 ($31.63) in a report on Wednesday, June 22nd.

About Mithra Pharmaceuticals

(Get Rating)

Mithra Pharmaceuticals SA develops, manufactures, and markets complex therapeutics in the areas of contraception, menopause, and hormone-dependent cancers in Europe and internationally. Its development candidates include Estelle, which has completed phase III clinical trial, which is a combined oral contraceptive; Donesta, which is in phase III clinical trial for estetrol-based oral hormone treatment.

Featured Stories

Receive News & Ratings for Mithra Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mithra Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.